https://orcid.org/0000-0003-3515-7537
References
- Partridge MR, Karlsson N, Small IR. Patient insight into the impact of chronic obstructive pulmonary disease in the morning: an internet survey. Curr Med Res Opin. 2009;25(8):2043–2048.
- Stephenson JJ, Cai Q, Mocarski M, et al. Impact and factors associated with nighttime and early morning symptoms among patients with chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis. 2015;10:577–586.
- Rutten FH, Cramer MJM, Lammers JWJ, et al. Heart failure and chronic obstructive pulmonary disease: an ignored combination? Eur J Heart Fail. 2006;8(7):706–711.
- Roche N, Small M, Broomfield S, et al. Real world COPD: association of morning symptoms with clinical and patient reported outcomes. COPD. 2013;10(6):679–686.
- Calverley PMA, Lee A, Towse L, et al. Effect of tiotropium bromide on circadian variation in airflow limitation in chronic obstructive pulmonary disease. Thorax. 2003;58(10):855–860.
- Krakowiak K, Durrington HJ. The role of the body clock in asthma and COPD: implication for treatment. Pulm Ther. 2018;4(1):29–43.
- van Noord JA, Aumann JL, Janssens E, et al. Effects of tiotropium with and without formoterol on airflow obstruction and resting hyperinflation in patients with COPD. Chest. 2006;129(3):509–517.
- Roche N, Chavannes NH, Miravitlles M. COPD symptoms in the morning: impact, evaluation and management. Respir Res. 2013;14(1):112.
- Postma DS, Koëter GH, vd Mark TW, et al. The effects of oral slow-release terbutaline on the circadian variation in spirometry and arterial blood gas levels in patients with chronic airflow obstruction. Chest. 1985;87(5):653–657.
- Kessler R, Partridge MR, Miravitlles M, et al. Symptom variability in patients with severe COPD: a pan-European cross-sectional study. Eur Respir J. 2011;37(2):264–272.
- Beeh KM, Beier J. The short, the long and the “ultra-long”: why duration of bronchodilator action matters in chronic obstructive pulmonary disease. Adv Ther. 2010;27(3):150–159.
- Mammen MJ, Pai V, Aaron SD, et al. Dual LABA/LAMA therapy versus LABA or LAMA monotherapy for chronic obstructive pulmonary disease. A systematic review and meta-analysis in support of the American Thoracic Society clinical practice guideline. Ann Am Thorac Soc. 2020;17(9):1133–1143.
- Ferguson GT, Brown N, Compton C, et al. Once-daily single-inhaler versus twice-daily multiple-inhaler triple therapy in patients with COPD: lung function and health status results from two replicate randomized controlled trials. Respir Res. 2020;21(1):131.
- Partridge MR, Schuermann W, Beckman O, et al. Effect on lung function and morning activities of budesonide/formoterol versus salmeterol/fluticasone in patients with COPD. Ther Adv Respir Dis. 2009;3(4):147–157.
- Terzano C, Petroianni A, Conti V, et al. Rational timing of combination therapy with tiotropium and formoterol in moderate and severe COPD. Respir Med. 2008;102(12):1701–1707.
- Bruguerolle B, Philip-Joet F, Parrel M, et al. Unequal twice-daily, sustained-release theophylline dosing in chronic obstructive pulmonary disease. Chronobiol Int. 1987;4(3):381–385.
- GOLD Reports. Global Initiative for Chronic Obstructive Lung Disease – GOLD; 2022 [cited 2022 Apr 5]. Available from: https://goldcopd.org/2022-gold-reports-2
- Partridge MR, Miravitlles M, Ståhl E, et al. Development and validation of the Capacity of Daily Living during the Morning questionnaire and the Global Chest Symptoms Questionnaire in COPD. Eur Respir J. 2010;36(1):96–104.